Long-term Effects of Finasteride on Invasive Urodynamics and Symptoms in Treatment of Patients with Bladder Outflow Obstruction Due to Benign Prostatic Hyperplasia

The Journal of Urology

Volumn 154, Issue 4, 1995, Pages 1466-1469

  Tammela, Teuvo L J ^a   Kontturi, Matti J ^a  

^a Division of Urology Tampere University Hospital and Department of Clinical Medicine University of Tampere Tampere and Oulu University Central Hospital Oulu Finland ^*

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

ADULT; AGED; ARTICLE; BLADDER NECK STENOSIS; DETRUSOR MUSCLE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; URODYNAMICS;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FINASTERIDE; HUMAN; MALE; MIDDLE AGE; PROSTATIC HYPERPLASIA; TIME FACTORS; URETHRAL OBSTRUCTION; URODYNAMICS;

EID: 0029081094     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66894-0     Document Type: Article

References (24)

1. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men.
2. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism.
3. The role of 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
4. Administration of MK-906, a 4-azasteroid compound results in marked suppression of serum dihydrotestosterone in healthy men
5. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group
6. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.
7. The Finasteride Study Group
8. Finasteride in the treatment of benign prostatic hyperplasia.
9. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
10. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
11. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia.
12. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia
13. The assessment of prostatic obstruction from urodynamic measurements and from residual urine.
14. The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology
15. Determination of prostate volume of transrectal ultrasound.
16. A new look at bladder neck obstruction by the Food and Drug Administration regulators: guide lines for investigation of benign prostatic hypertrophy.
17. Computer analysis of prostatism a clinical application of the computer program CLIM
18. Bladder outlet obstruction versus impaired detrusor contractility: the role of uroflow.
19. Transurethral versus transvesical prostatectomy. Clinical, urodynamic, renographic and economic aspects. A randomized study
20. Male peak urinary flow rate: relationships to volume voided and age.
21. Uroflowmetry in asymptomatic elderly males.
22. The effect of age on the autonomic innervation of the urinary bladder.
23. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
24. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.